Skip to main content

$11.22 -0.22 (-1.92%)

High

$11.49

Low

$11.20

Trades

4,718

Turnover

$7,499,551

Volume

664,557
30 June 2023 at 4:12pm
Register to track TLX and receive email alerts.

ASX Announcements (7d)

-

Twitter Mentions (7d)

0+

AFR Articles (7d)

-

News Articles (7d)

1+
Subject
TLX Ann: Appendix 4E and 2022 Annual Report

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Telix Full Year Results and Investor Conference Call Details

TLX Ann: Investor briefing on ASCO-GU Zircon Phase III Results

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Q4 2022 Business update to accompany quarterly results

TLX Ann: Appendix 4C and Activities Report - December 2022 Quarter

TLX Ann: Notification of upcoming quarterly results and investor call

TLX Ann: Webcast link correction - JP Morgan Conference Presentation

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: JP Morgan Healthcare Conference Presentation

TLX Ann: JP Morgan Healthcare Conference and Trading Update

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: ZIRCON Ph III Renal Cancer Study to be Presented at ASCO GU

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: App 3Y Change in Director Interests - T Olsen

TLX Ann: Leadership Changes, including Company Secretary Appointment

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Release of shares from voluntary escrow

TLX Ann: Telix Acquires Optimal Tracers

TLX Ann: Appendix 3Y - Change of Directors Interest Notice

TLX Ann: Cleansing Notice

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Cleansing Notice

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: Application for quotation of securities - TLX

TLX Ann: ZIRCON Ph III Imaging Study - Top-Line data presentation

TLX Ann: ZIRCON Ph III Imaging Study - Positive Top-Line Results

TLX Ann: Notification regarding unquoted securities - TLX

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Q3 2022 Business Update to accompany quarterly results

TLX Ann: Appendix 4C and Activities Report - September 2022 Quarter

TLX Ann: TLX250-CDx Indication Expansion - Preliminary Data

TLX Ann: Expansion of partnership with GE Healthcare in PET imaging

TLX Ann: Chinese NMPA approves Phase III study of TLX591-CDx

TLX Ann: Notification of upcoming quarterly results and investor call

TLX Ann: Health Canada Approves Illuccix for Prostate Cancer Imaging

TLX Ann: Chinese NMPA Approves TLX250 Phase III registration study

TLX Ann: Telix Withdraws Marketing Application for Illuccix in Europe

TLX Ann: Final IPAX-1 Study Data Confirms Safety Tolerability Profile

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Application for quotation of securities - TLX

TLX Ann: Notification of cessation of securities - TLX

TLX Ann: Ceasing to be a substantial holder

TLX Ann: 1H 2022 - Results Presentation

Register to track TLX and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC